{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:06Z","timestamp":1766023026737,"version":"3.48.0"},"reference-count":34,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/ugtw5471","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T09:32:32Z","timestamp":1712223152000},"page":"768-780","source":"Crossref","is-referenced-by-count":0,"title":["Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease"],"prefix":"10.62347","volume":"16","author":[{"given":"Xiao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2016.164","article-title":"The role of phosphate in kidney disease","volume":"13","author":"MG","year":"2017","unstructured":"Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M and Fouque D; ERA-EDTA Working Group on Chronic Kidney Disease-Mineral and Bone Disorders and the European Renal Nutrition Working Group. The role of phosphate in kidney disease. Nat Rev Nephrol 2017; 13: 27-38.","journal-title":"Nat Rev Nephrol"},{"key":"ref1","unstructured":"Caravaca F, García-Pino G, Martínez-Gallardo R, Ferreira-Morong F, Luna E, Alvarado R, Ruiz-Donoso E and Chávez E. Increased serum phosphate concentrations in patients with advanced chronic kidney disease treated with diuretics. Nefrologia 2013; 33: 486-94."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Copland M, Komenda P, Weinhandl ED, McCullough PA and Morfin JA. Intensive hemodialysis, mineral and bone disorder, and phosphate binder use. Am J Kidney Dis 2016; 68: S24-S32.","DOI":"10.1053\/j.ajkd.2016.05.024"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.pop.2020.08.001","article-title":"Chronic kidney disease","volume":"47","author":"Charles","year":"2020","unstructured":"Charles C and Ferris AH. Chronic kidney disease. Prim Care 2020; 47: 585-595.","journal-title":"Prim Care"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/nu13041273","article-title":"Phosphate, microbiota and CKD","volume":"13","author":"Favero","year":"2021","unstructured":"Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B and Sanchez-Niño MD. Phosphate, microbiota and CKD. Nutrients 2021; 13: 1273.","journal-title":"Nutrients"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/sdi.12694","article-title":"Hemodialysis-induced cardiovascular disease","volume":"31","author":"Ahmadmehrabi","year":"2018","unstructured":"Ahmadmehrabi S and Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial 2018; 31: 258-267.","journal-title":"Semin Dial"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Almquist M, Isaksson E and Clyne N. The treatment of renal hyperparathyroidism. Endocr Relat Cancer 2020; 27: R21-R34.","DOI":"10.1530\/ERC-19-0284"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.jrn.2020.02.003","article-title":"Management of hyperphosphatemia in end-stage renal disease: a new paradigm","volume":"31","author":"Rastogi","year":"2021","unstructured":"Rastogi A, Bhatt N, Rossetti S and Beto J. Management of hyperphosphatemia in end-stage renal disease: a new paradigm. J Ren Nutr 2021; 31: 21-34.","journal-title":"J Ren Nutr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/cts.13151","article-title":"Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease","volume":"15","author":"Mason","year":"2022","unstructured":"Mason DL, Godugu K, Nnani D and Mousa SA. Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease. Clin Transl Sci 2022; 15: 353-360.","journal-title":"Clin Transl Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD-mineral bone disease","volume":"6","author":"SM","year":"2021","unstructured":"Sprague SM, Martin KJ and Coyne DW. Phosphate balance and CKD-mineral bone disease. Kidney Int Rep 2021; 6: 2049-2058.","journal-title":"Kidney Int Rep"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Wang X, Xu Y, Yu X, Dey A, Zhang HY, Zink CM, Wodka D, Porter G, Matter WF, Porras L, Reidy CA, Peterson JA, Mattioni BE, Haas JV, Kowala MC and Wetterau JR. Effects of pharmacological inhibition of the sodium-dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models. Pharmacol Res Perspect 2022; 10: e00938.","DOI":"10.1002\/prp2.938"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","unstructured":"Vervloet MG and van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int 2018; 93: 1060-1072.","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Elseviers M and De Vos JY. The use of phosphate binders: data from contributors to the European Practice Database. J Ren Care 2009; 35 Suppl 1: 14-8.","DOI":"10.1111\/j.1755-6686.2009.00051.x"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","article-title":"Hyperphosphatemia management in patients with chronic kidney disease","volume":"24","author":"Shaman","year":"2016","unstructured":"Shaman AM and Kowalski SR. Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J 2016; 24: 494-505.","journal-title":"Saudi Pharm J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrneph.2011.112","article-title":"Pharmacology, efficacy and safety of oral phosphate binders","volume":"7","author":"AJ","year":"2011","unstructured":"Hutchison AJ, Smith CP and Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011; 7: 578-89.","journal-title":"Nat Rev Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T and Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-96.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3748\/wjg.14.2615","article-title":"Lower gastrointestinal bleeding: association with Sevelamer use","volume":"14","author":"Madan","year":"2008","unstructured":"Madan P, Bhayana S, Chandra P and Hughes JI. Lower gastrointestinal bleeding: association with Sevelamer use. World J Gastroenterol 2008; 14: 2615-6.","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2009","unstructured":"Sabbagh Y, O’Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C and Schiavi SC. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20: 2348-58.","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","article-title":"Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure","volume":"20","author":"Eto","year":"2005","unstructured":"Eto N, Miyata Y, Ohno H and Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20: 1378-84.","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD","volume":"23","author":"SC","year":"2012","unstructured":"Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S and Sabbagh Y. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 2012; 23: 1691-700.","journal-title":"J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Hong SH, Minai-Tehrani A, Chang SH, Jiang HL, Lee S, Lee AY, Seo HW, Chae C, Beck GR Jr and Cho MH. Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS One 2013; 8: e77121.","DOI":"10.1371\/journal.pone.0077121"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Berndt TJ, Pfeifer JD, Knox FG, Kempson SA and Dousa TP. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 1982; 242: F447-52.","DOI":"10.1152\/ajprenal.1982.242.5.F447"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI110163","article-title":"Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat","volume":"67","author":"Kempson","year":"1981","unstructured":"Kempson SA, Colon-Otero G, Ou SY, Turner ST and Dousa TP. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981; 67: 1347-60.","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-013-0024-6","article-title":"Use of nicotinamide to treat hyperphosphatemia in dialysis patients","volume":"13","author":"Lenglet","year":"2013","unstructured":"Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M and Massy ZA. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D 2013; 13: 165-73.","journal-title":"Drugs R D"},{"key":"ref24","unstructured":"Shahbazian H, Zafar Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F and Lashkarara GR. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia 2011; 31: 58-65."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/jn\/nxaa148","article-title":"Supplemental nicotinamide dose-dependently regulates body phosphorus excretion via altering type II sodium-phosphate co-transporter expressions in laying hens","volume":"150","author":"Ren","year":"2020","unstructured":"Ren ZZ, Yan JK, Pan C, Liu YL, Wen HY, Yang X, Huang XH, Lei XG and Yang XJ. Supplemental nicotinamide dose-dependently regulates body phosphorus excretion via altering type II sodium-phosphate co-transporter expressions in laying hens. J Nutr 2020; 150: 2070-2076.","journal-title":"J Nutr"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Saito A, Nikolaidis NM, Amlal H, Uehara Y, Gardner JC, LaSance K, Pitstick LB, Bridges JP, Wikenheiser-Brokamp KA, McGraw DW, Woods JC, Sabbagh Y, Schiavi SC, Altinişik G, Jakopović M, Inoue Y and McCormack FX. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. Sci Transl Med 2015; 7: 313ra181.","DOI":"10.1126\/scitranslmed.aac8577"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41467-023-36810-8","article-title":"Insights into pulmonary phosphate homeostasis and osteoclastogenesis emerge from the study of pulmonary alveolar microlithiasis","volume":"14","author":"Uehara","year":"2023","unstructured":"Uehara Y, Tanaka Y, Zhao S, Nikolaidis NM, Pitstick LB, Wu H, Yu JJ, Zhang E, Hasegawa Y, Noel JG, Gardner JC, Kopras EJ, Haffey WD, Greis KD, Guo J, Woods JC, Wikenheiser-Brokamp KA, Kyle JE, Ansong C, Teitelbaum SL, Inoue Y, Altinişik G, Xu Y and McCormack FX. Insights into pulmonary phosphate homeostasis and osteoclastogenesis emerge from the study of pulmonary alveolar microlithiasis. Nat Commun 2023; 14: 1205.","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1080\/0886022X.2021.1986068","article-title":"Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis","volume":"43","author":"Zhao","year":"2021","unstructured":"Zhao L, Liu A and Xu G. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis. Ren Fail 2021; 43: 1378-1393.","journal-title":"Ren Fail"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/j.ackd.2022.04.002","article-title":"Pediatric mineral and bone disorder of chronic kidney disease and cardiovascular disease","volume":"29","author":"Kusumi","year":"2022","unstructured":"Kusumi K, Kremsdorf R, Kakajiwala A and Mahan JD. Pediatric mineral and bone disorder of chronic kidney disease and cardiovascular disease. Adv Chronic Kidney Dis 2022; 29: 275-282.","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.kint.2017.11.022","article-title":"The sodium phosphate cotransporter family and nicotinamide phosphoribosyltransferase contribute to the daily oscillation of plasma inorganic phosphate concentration","volume":"93","author":"Miyagawa","year":"2018","unstructured":"Miyagawa A, Tatsumi S, Takahama W, Fujii O, Nagamoto K, Kinoshita E, Nomura K, Ikuta K, Fujii T, Hanazaki A, Kaneko I, Segawa H and Miyamoto KI. The sodium phosphate cotransporter family and nicotinamide phosphoribosyltransferase contribute to the daily oscillation of plasma inorganic phosphate concentration. Kidney Int 2018; 93: 1073-1085.","journal-title":"Kidney Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2017.08.003","article-title":"NPT-IIb inhibition does not improve hyperphosphatemia in CKD","volume":"3","author":"Larsson","year":"2018","unstructured":"Larsson TE, Kameoka C, Nakajo I, Taniuchi Y, Yoshida S, Akizawa T and Smulders RA. NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep 2018; 3: 73-80.","journal-title":"Kidney Int Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1086\/508263","article-title":"Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis","volume":"79","author":"Corut","year":"2006","unstructured":"Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, Calisir H, Yildirim Z, Gocmen A and Tolun A. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006; 79: 650-6.","journal-title":"Am J Hum Genet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G and Chonchol M; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-22.","journal-title":"J Am Soc Nephrol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/3\/ajtr0155484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:16Z","timestamp":1766022736000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/3\/ajtr0155484.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/ugtw5471","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2024]]}}}